AbbVie Acquires Biotech Apogee Therapeutics in $10.9 Billion Deal

AbbVie has agreed to acquire biotech firm Apogee Therapeutics for $10.9 billion, marking its largest acquisition in over five years, according to a statement from the pharmaceutical giant. The deal, which values Apogee at $135.11 per share—a 49% premium to its closing price on Thursday—signals a strategic push to expand its immunology and inflammation drug pipeline. Apogee’s shares surged 47% to $132.70 in early New York trading, while AbbVie’s stock rose 4.5% to $226.22, according to the Financial Times.

What is the financial detail of the acquisition?

The transaction, which includes cash payments to Apogee’s shareholders, underscores AbbVie’s focus on securing innovative therapies amid patent expirations for its blockbuster drug Humira. The deal follows a $1.3 billion financing and royalty agreement Apogee struck with Blackstone last month, which included an option for the biotech to explore a sale, as reported by Bloomberg. LSEG data shows over $200 billion in healthcare acquisitions have been announced this year, driven by large pharmaceutical companies seeking to bolster pipelines.

Why is this deal significant for AbbVie’s portfolio?

Apogee’s lead drug, zumilokibart, is a long-acting treatment for atopic dermatitis, an inflammatory skin condition affecting over 200 million people globally. The therapy, which could also target asthma and other inflammatory diseases, is set to begin phase-three trials later this year. AbbVie, which has shifted Humira patients to newer drugs Skyrizi and Rinvoq, aims to strengthen its immunology leadership, with CEO Robert Michael stating the acquisition “adds highly differentiated clinical-stage assets” to its portfolio, according to a company statement.

How does this fit into broader biotech merger trends?

The deal aligns with a surge in biotech M&A as major pharmaceutical firms race to offset revenue losses from expiring patents. Morgan Stanley highlighted in a recent report that small and mid-cap biotechs remain attractive targets due to their innovative pipelines. AbbVie’s previous acquisitions include a $10.1 billion deal for oncology firm Immunogen in 2024 and an $8.7 billion purchase of psychiatric drug developer Cerevel Therapeutics, though the latter’s lead drug later failed in trials. The trend reflects a risk-reward strategy for giants seeking to sustain growth in a competitive market.

What are the implications for Apogee’s development?

Apogee, founded in 2022 by Venrock and Fairmount, had already secured $1.3 billion in financing to advance zumilokibart. The sale to AbbVie provides immediate liquidity for shareholders while accelerating the drug’s development. Analysts note the acquisition could position zumilokibart as a rival to Dupixent, a $17.8 billion-a-year treatment co-developed by Sanofi and Regeneron. Evan Seigerman of BMO Capital Markets described the deal as a “natural fit” for AbbVie’s focus on longer dosing intervals in inflammatory diseases, according to a Friday report.

The transaction is expected to close in the second half of 2025, pending regulatory approvals. AbbVie’s legal advisors include Morgan Stanley and Paul Weiss, while Apogee was represented by Jefferies, Goldman Sachs, and Kirkland & Ellis, according to the Financial Times.